English
L-Alanyl-L-Glutamine (Ala-Gln) Product Introduction
Created on 09.02
L-Alanyl-L-glutamine
(Ala-Gln) Product Introduction
I. Product Source
L-Alanyl-L-glutamine is a functional dipeptide formed by the linkage of L-alanine and L-glutamine via a peptide bond. Its industrial production primarily employs two major technological routes: the chemical synthesis method and the biosynthetic method; among these, enzymatic biosynthesis is currently the mainstream process for manufacturing pharmaceutical-grade products.
1.The chemical synthesis method employs a classical approach in which D-2-chloropropionyl chloride and L-glutamamide serve as starting materials; these react via a condensation reaction to form an intermediate, which is then subjected to high-pressure ammonolysis to yield the target product. When optimized, the overall yield can exceed 43%, and the HPLC purity surpasses 98%. Alternatively, a benzoylcarbonyl-protected–condensation–hydrogenation route can be utilized, yielding up to 65%. This route features readily available raw materials and a well-established process; however, it is characterized by the generation of numerous by-products, high purification costs, and significant environmental concerns, making it primarily suitable for the production of industrial-grade raw materials.
2.Biological synthesis method (the mainstream industrial approach)
· · Microbial fermentation method: Escherichia coli or Pichia pastoris are genetically
engineered to overexpress L-amino acid ligase while simultaneously knocking out the dipeptide degradation enzyme and transport system; the L-alanine and L-glutamate are then used as substrates for direct fermentation synthesis. The fermentation yield can reach 24.70 g/L, with a production cycle of approximately 47 h; this approach is environmentally friendly and safe, but its production efficiency is relatively low.
· · Enzymatic catalysis method (preferred process): Using α-aminoacyltransferase as the core catalyst and L-alanine methyl ester and L-glutamine as substrates, the product concentration can reach 106.61 g/L within 25 minutes; this process requires no ATP energy input, features a short reaction cycle, high product concentration, and low levels of impurities and endotoxins. It is currently the mainstream production technology for pharmaceutical-grade proline-glutamine dipeptides and can directly yield high-purity active pharmaceutical ingredients (APIs) that meet injectable-grade standards.
II. Efficacy and Actions
Core physiological benefits
1.Glutamine homeostatic delivery: Upon entering the human body, glutamine is precisely hydrolyzed by peptidases present in the tissues into L-alanine and L-glutamine, thereby continuously supplying the body with conditionally essential amino acids. This compensates for the deficit in endogenous glutamine synthesis during high-metabolic states such as trauma, infection, or postoperative periods, and helps maintain a stable plasma glutamine concentration.
2. Maintaining intestinal barrier integrity: As the preferred energy substrate for intestinal mucosal epithelial cells, it helps reduce intestinal mucosal atrophy, preserve the tight junction structure of the intestine, and lower the risk of intestinal bacterial translocation and endotoxin release; it serves as a core nutrient for protecting intestinal function in critically ill patients and can significantly reduce the incidence of postoperative infectious complications (Chinese Medical Journal...).
3.Promotes protein synthesis and inhibits muscle catabolism: By inhibiting the ubiquitin–proteasome degradation pathway and regulating mTOR-mediated synthetic metabolic signaling, this approach significantly reduces the rate of muscle protein degradation in patients with trauma, prolonged fasting, or mechanical ventilation, ameliorates negative nitrogen balance, minimizes skeletal muscle loss, and shortens the postoperative recovery period.
4.Enhanced immune and anti-inflammatory effects: Provides energy to immune cells such as lymphocytes and macrophages, maintains the function of the gut-associated lymphoid tissue (GALT), and elevates CD4+ cell levels; simultaneously regulates the release of pro-inflammatory mediators, mitigates oxidative stress-induced damage, and ameliorates the immunosuppressive state following infection or radiotherapy/chemotherapy.
The core advantage of comparing free L-glutamine
Comparison Dimension | Free L-glutamine | L-Alanyl-L-glutamine |
Water solubility (25°C) | Approx. 35 g/L | >500 g/L (approximately 15-fold concentration); suitable for preparing high-concentration formulations. |
stability of solution | The aqueous solution is prone to spontaneous degradation into ammonia and pyroglutamic acid (which is neurotoxic); the solution can be stored for only 2–3 weeks at 4°C. | The aqueous solution is highly stable, does not undergo spontaneous degradation, is compatible with 121°C high-temperature sterilization, and can be stored at 4°C for 12–24 months. |
Bioavailability characteristics | Rapid absorption can cause fluctuations in blood drug concentration; extensive degradation may lead to ammonia accumulation. | Sustained-release delivery, on-demand release, absence of amphotericity, and higher glutamine utilization rate |
Administration convenience | Low solubility; administration of high doses can significantly increase the patient's fluid load. | Excessively high solubility allows for a significant reduction in infusion volume, making it particularly suitable for critically ill or fluid-restricted patients. |
III. Application Scenarios and Market Conditions
Core application areas and end-product offerings
1. Pharmaceutical Clinical Practice (Core Mature Field)
·· Indications: Patients in catabolic or hypermetabolic states, including those following surgery, trauma, burns, severe infections, critical care in the ICU, undergoing tumor radiotherapy or chemotherapy, or after organ transplantation.
· Final product: Alanine-Glutamine Injection – a standard core component of parenteral nutrition formulations; must be used in combination with Amino Acids Injection.
2. Sports Nutrition (High-Growth Sector)
· · Application value: As a substitute for conventional glutamine, it is used for post-exercise muscle repair, alleviating central fatigue, and maintaining gut health and immune status in athletes, addressing the limitations associated with conventional glutamine – such as low solubility upon mixing and rapid degradation leading to reduced efficacy.
· · End-product offerings – including professional sports nutrition supplements such as sports recovery powder, whey protein compound powder, energy drinks, and protein bars – represent the mainstream glutamine raw material form used by premium sports nutrition brands in Europe and North America.
3.Cell culture and biopharmaceuticals
·· Application value: As a stable alternative to glutamine in cell culture media, it prevents ammonia toxicity resulting from the degradation of free glutamine, extends the cell culture cycle, enhances the expression yield and glycosylation quality of recombinant proteins and antibody-based therapeutics, and is particularly suitable for high-density bioreactors and long-term culture processes.
· · End products: Serum-free cell culture medium and specialized cell culture additives.
4.Special and Functional Foods
·· Application scenarios: Special medical foods for infants and young children; nutritional supplements for the elderly; dietary interventions for individuals with gastrointestinal disorders – designed to improve the intestinal barrier function and nutrient absorption.
· ·End-product range: Special Medical Purpose Formula Food Powder, Intestinal Care Functional Foods, and Nutritional Meal Replacements.
Market Trends
·· Global Market: The global market size is projected to reach USD 310–590 million by 2026, with a compound annual growth rate (CAGR) of 5.5%–7%; the market exhibits a tiered structure: the pharmaceutical-grade segment is dominated by a small number of companies—including Fresenius Kärper and Ajinomoto—while the food-grade segment is seeing an increasing number of participants; sports nutrition represents the fastest-growing downstream segment, accounting for 38.5% of total demand.
· Long-term growth drivers – including the upgrading of standardized clinical nutrition prescribing practices, the expanding demand in critical care medicine and oncology, the evolving consumer trends in sports nutrition, and the capacity expansion in the biopharmaceutical CDMO sector – collectively underpin the sustained and steady growth of these products.
